BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 340033)

  • 1. Treatment of metastatic breast cancer with adriamycin-cyclophosphamide induction followed by alternating combination therapy.
    Abeloff MD; Ettinger DS
    Cancer Treat Rep; 1977 Dec; 61(9):1685-9. PubMed ID: 340033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new six-drug antiblastic regimen (R 14) at low doses (micropolychemotherapy) compared to CMF in the treatment of metastatic breast cancer: phase III study.
    Pannuti F; Iafelice G; Martoni A; Fruet F; Angelelli B; Casadei M
    Chemioterapia; 1984 Aug; 3(4):216-9. PubMed ID: 6398121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolonged disease-free survival in advanced breast cancer treated with "super-CMF" adriamycin: an alternating regimen employing high-dose methotrexate with citrovorum factor rescue.
    Henderson IC; Gelman R; Canellos GP; Frei E
    Cancer Treat Rep; 1981; 65 Suppl 1():67-75. PubMed ID: 6976832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor effect of combination of cyclophosphamide, adriamycin and platinum (CAP) versus cyclophosphamide, adriamycin and 5-fluorouracil (CAF) in metastatic breast cancer.
    Tzekova V; Velikova M; Koynov K; Micheva D; Donchev T
    Neoplasma; 1991; 38(6):603-7. PubMed ID: 1766485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
    Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
    Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial.
    Hainsworth JD; Jolivet J; Birch R; Hopkins LG; Greco FA
    Cancer; 1997 Feb; 79(4):740-8. PubMed ID: 9024712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of adriamycin in metastatic breast cancer resistant to a combination regimen with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prdnisone.
    Frederiksen PL; Joergensen ST; Roesdahl K; Thomsen J; Mouridsen HT
    Cancer Treat Rep; 1978 Mar; 62(3):449-50. PubMed ID: 348314
    [No Abstract]   [Full Text] [Related]  

  • 8. Phase I/II study of dose-intense doxorubicin/paclitaxel/cyclophosphamide with peripheral blood progenitor cells and cytokine support in patients with metastatic breast cancer.
    Rahman Z; Champlin R; Rondon G; Frye D; Valero V; Mehra R; Hortobagyi G
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-77-S17-80. PubMed ID: 9374100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Combination chemotherapy in metastatic breast cancer].
    Kuten A; Lev L; Mohaliver J; Robinson E
    Harefuah; 1981 Feb; 100(3):118-20. PubMed ID: 7262675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and Fluorouracil in operable breast cancer.
    Bonadonna G; Zambetti M; Moliterni A; Gianni L; Valagussa P
    J Clin Oncol; 2004 May; 22(9):1614-20. PubMed ID: 15117983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II trial of cyclophosphamide, methotrexate, 5-fluorouracil, and prednisolone rapidly alternating with doxorubicin and vincristine (CMFP/AV) in advanced breast cancer.
    Rischin D; Bishop JF; Olver IN; Laidlaw CR; Zimet A; Jeal P; Dipell JF
    Am J Clin Oncol; 1992 Oct; 15(5):392-4. PubMed ID: 1524039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First, second and third line chemotherapy programs in metastatic breast carcinoma.
    Rizel S; Sulkes A; Gez E; Brufman G; Biran S
    Isr J Med Sci; 1981; 17(9-10):946-53. PubMed ID: 6171542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of a combination of vinorelbine, cyclophosphamide and 5-fluorouracil in the treatment of advanced breast cancer.
    Ardavanis A; Extra JM; Espié M; Cuvier C; Marty M
    In Vivo; 1998; 12(5):559-62. PubMed ID: 9827368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Encouraging results with cytostatic therapy in metastasizing breast cancer (author's transl)].
    Michlmayr G; Kratzer H; Denz H; Huber H
    Wien Klin Wochenschr; 1981 Mar; 93(6):205-7. PubMed ID: 7281697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update: the M.D. Anderson Cancer Center experience with paclitaxel in the management of breast carcinoma.
    Holmes FA
    Semin Oncol; 1995 Aug; 22(4 Suppl 8):9-15. PubMed ID: 7543702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salvage treatment of patients relapsing after breast cancer adjuvant chemotherapy.
    Wendt AG; Jones SE; Salmon SE
    Cancer Treat Rep; 1980; 64(2-3):269-73. PubMed ID: 6893293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclophosphamide, methotrexate, and chronic oral tegafur modulated by folinic acid in the treatment of patients with advanced breast carcinoma.
    Ribas A; Albanell J; Solé-Calvo LA; Gallardo E; Bellmunt J; Vera R; Vidal R; Carulla J; Baselga J
    Cancer; 1998 Mar; 82(5):878-85. PubMed ID: 9486577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized comparison of two combination chemotherapy regimens containing doxorubicin in patients with metastatic breast cancer: a Western Cancer Study Group trial.
    Irwin LE; Chlebowski RT; Weiner JM; Reynolds R; Pugh RP; Ryden VM; Bateman JR
    Cancer Treat Rep; 1980; 64(8-9):981-4. PubMed ID: 7004635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of combined vincristine, adriamycin, cyclophosphamide, and methotrexate with citrovorum factor factor rescue in metastatic breast cancer.
    Mattsson W; Arwidi A; von Eyben F; Lindholm CE
    Cancer Treat Rep; 1977 Nov; 61(8):1527-31. PubMed ID: 303543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.